Anticardiolipin antibody levels were measured in 57 patients with Mycoplasma pneumoniae infection and 21 patients with other infections. Significantly more patients in the mycoplamsa group had increased IgM and IgG anticardiolipin. Within the mycoplasma group significantly higher titres were found in patients with severe infection (assessed by need for hospital admission) and in patients with cold agglutinins. A tendency for particularly high titres to occur in patients with extra-pulmonary complications was identified.
Introduction
Antibodies to negatively charged phospholipids, such as cardiolipin, are associated with nonvasculitic thrombosis, recurrent spontaneous abortion, thrombocytopenia and neurological disease.'2 This association was first noted in systemic lupus erythematosus (SLE) where antiphospholipid antibodies (aPL) are very closely linked with3 (but are not identical to4) the so-called 'lupus anticoagulant'. Recently, patients have been described with high titre aPL, thrombosis and recurrent abortion but with no evidence of connective tissue disease or other immunopathology. These patients may constitute a 'primary antiphospholipid antibody syndrome'.56 Low titre aPL have been demonstrated in a number of other conditions: acute infections (infectious mononucleosis,7 human immunodeficiency virus infection8, malignancy, ischaemic heart disease9 and in the healthy elderly."' The significance of this is unclear; in general it is felt to be representative of the low grade autoimmune responses of little functional significance which accompany tissue damage and ageing" (in contrast with the aPL responses in SLE and the primary aPL syndrome where there is some evidence that these antibodies play a direct role in the pathogenesis of the associated complications '2) .
During development of an enzyme-linked immunosorbent assay (ELISA) for aPL (using cardiolipin as antigen) at the North West Regional Immunology Service, large numbers of serum samples from normal controls and patients were analysed. In addition to the expected positive results from patients with SLE and low titre positives from other conditions, it was noted that in a few patients, markedly increased titres of aPL occurred unexpectedly. Particularly high titres were noted in the serum of one patient with Mycoplasma pneumoniae infection. This was interesting in view of the recognized extra pulmonary complications of mycoplasma infection, such as haemolysis, neurological disease'3 and stroke,'4"5 some of which may have an immunological basis.
We therefore examined the hypothesis that patients with Mycoplasma pneumoniae infection were particularly likely to develop high titres of aPL. A retrospective analysis of sera from patients with known M. pneumoniae infection was undertaken. We attempted to correlate aPL levels with severity of illness and complications.
We also had the opportunity to study serum from one patient with an ischaemic stroke in association with M. pneumoniae infection (not from the retrospective series).
Materials and methods

Patients
Details of the patient with stroke in association with Mycoplasma pneumoniae infection have been previously reported.'4 Briefly, a 31 year old previously fit male presented with a 3-week history ANTIPHOSPHOLIPID ANTIBODIES AND M. PNEUMONIAE INFECTION 357 of malaise, dyspnoea and cough and a 1-day history of drowsiness and left sided weakness. Chest X-ray revealed left sided pneumonic changes, a computed tomographic (CT) scan of the head showed a right cerebral hemisphere infarct and serological testing revealed a four-fold increase in complement fixation titres to M. pneumoniae. No source for embolism or other risk factor for stroke was identified.
Serum samples were obtained from all patients with serological evidence of M. pneumoniae infection over a 2-year period (January 1986-January 1988) detected at the North Manchester Regional Virus Laboratory. Names of patients were obtained from the laboratory weekly returns to the Communicable Disease Surveillance Centre. All sera had been stored at -40°C and aPL levels were measured within 48 hours of thawing. Where possible, paired serum samples were retrieved (one from the acute phase of the illness and the other taken 7-14 days later), but in most cases only the second (convalescent) sample was available. Serological evidence of M. pneumoniae infection was defined as a four-fold increase in complement fixation (CF) titre between the first and second samples, or a single titre greater than or equal to 1/320 in the context of an illness consistent with M. pneumoniae infection. Sera were obtained from 57 patients in all (32 female, 25 21 -58) were also tested in order to provide further validation for the normal ranges used. The plates were incubated for 60 minutes at room temperature and then washed three times in PBS. One hundred 1tl of peroxidase conjugated rabbit antibody to human IgG or IgM (Dako) diluted 1/500 in NCS/PBS was added to each well.
Following a further 1 hour incubation the plates were washed three times in PBS and 200 gl of I mM-ABTS (Sigma A-1888) containing 0.1 mMhydrogen peroxide in citrate phosphate buffer (pH 5.4) was added to each well. The reactions were then allowed to develop until the optical density of the 1/10 dilution of the standard serum read approximately 1 
Results
The patient with mycoplasma infection and a stroke had IgM and IgG anticardiolipin (aCL) levels of 46 and 7 respectively (sample taken 2 days after admission to hospital).
The anticardiolipin titres from the retrospective study are shown in Figure 1 (for patients with paired samples, only the values from the second sample are shown). The median absolute values were significantly higher in the mycoplasma groups (Mann-Whitney U test, P <0.001 for both IgM and IgG aCL). Significantly more patients in the mycoplasma group had IgM and IgG anticardiolipin titres outside the normal range and, for IgM aCL, greater than twice the normal range (Table I) .
Analysis of the 17 paired samples is shown in rone), one developed erythema multiforme (the patient without pneumonia) and one (Down syndrome) had repeated hospital admissions. No patient died. Of the patients treated at home, 7 had evidence of pneumonia and 6 had upper respiratory tract infections or influenza-like illnesses. Five patients (1 hospitalized, 4 managed at home) had prolonged (>2 months) post-infectious respiratory symptoms and malaise. No other complications were recorded. In the control infection group 9 patients were hospitalized and 12 treated at home (not significantly different from mycoplasma group x2= 3.5, P>0.05).
The distribution of positive anticardiolipin titres in the home treated and hospitalized groups were shown in Table III . Significantly more patients in the hospitalized group had IgM anticardiolipin titres > 30 units. The 3 patients with a complicated course had titres of IgM and IgG anticardiolipin of 47 U and 20 U (facial nerve palsies), 35 and 31 (Down syndrome, repeated admissions) and 33 U and 14 U (erythema multiforme).
Cold agglutinins were measured in 12 patients and were positive in 5 (all greater than 1:512). IgM anticardiolipin (but not IgG) titres were significantly higher in the group with positive cold agglutinins ( Figure 2 ). There was, however, a significant positive correlation in the mycoplasma group between IgM and IgG anticardiolipin levels (Spearman's rank correlation coefficient r, = 0.45 (n = 58): P<0.01). The hypothesis was therefore examined that high titres of IgM anticardiolipin might be due to IgM rheumatoid factor (IgM RF) binding to low titre IgG anticardiolipin. IgM RF was measured in 23 patients; the 16 patients with the highest IgM anticardiolipin titres and 7 patients with titres in the normal range. Positive results (mainly low titre) were found in 8/16 patients with high levels and 1/7 with low (see Figure 3 ). There was, however, no simple relation between IgM RF and anticardiolipin titre and the three patients with the highest anticardiolipin titres had no detectable IgM RF in this assay.
The presence of other autoantibodies was also assessed in these 23 patients. Two patients had low titre (1/20) antinuclear antibodies, with a speckled pattern (interestingly, these were the patients with The susceptibility ofpatients with Down syndrome was also noted in the retrospective series. We have confirmed the presence ofantiphospholipid antibodies in acute infection. Our results suggest that these antibodies occur in more than 50% of patients with mycoplasma infection and that these patients may develop higher levels of antibody when compared to individuals with other infections (although this should be interpreted cautiously, as the range of infections in the control group was low and was limited to those infections serologically investigated in a hospital virology laboratory. There is also a suggestion, although not statistically significant, that the control group had less severe disease).
These results contrast with those of Vaarala et al. ' 9 who found no selective increase among patients with mycoplasma infection. However, the anticardiolipin assay in that study used Tween 20 (a detergent) as a washing and blocking agent. In our experience this removes most of the phospholipid from the microtitre plates. Examination of the IgG anticardiolipin responses particularly in the paired sera, suggest that the IgM response is associated with subsequent development of IgG in around 50-70% of cases. The results from the paired sera also suggest that the IgM response is sustained to at least 7-14 days in the majority of cases. We feel this validates the use of principally convalescent sera in this series.
It is unlikely that the high IgM responses seen in this study can be explained in terms of rheumatoid factor activity, although some amplifying effect of rheumatoid factor cannot be ruled out in the cases in which it was present.
Two contrasting models (not entirely mutually exclusive) can be developed for the relationship between antiphospholipid antibodies and M. pneumoniae infection. Firstly, the antibodies may be representative of the low grade immune responses (principally IgM, often low affinity and highly cross-reactive) to intracellular constituents seen in tissue damage due to many causes.'0,20 The specificity for mycoplasma infection, the tendency to develop IgG antibodies and the low levels of other autoantibodies would tend to argue against this. Secondly, the antibody production may reflect some particular tendency of M. pneumoniae to stimulate autoantibody production (whether by antigenic cross-reactivity on some other immunomodulatory effect). The correlation with cold agglutinin production (usually identified with IgM anti-I21) is interesting. It is perhaps worthy of note that the 4 patients in which other autoantibodies were detected by immunofluorescence were all cases with high anticardiolipin binding and/or extrapulmonary complications.
The results presented here suggest that elevations in anticardiolipin titre are more marked in patients with severe infection (assessed in terms of the need for hospital admission). There is a possible correlation of antiphospholipid titre with cold agglutinin production, but the numbers are small and warrant further study.
The possibility that high levels of anticardiolipin binding may be predictive (and even possibly pathogenetic) of extrapulmonary complications in M. pneumoniae infection deserves further consideration. The numbers presented here do not justify such a conclusion but it is interesting to note that the two patients with the facial nerve palsies and the stroke had the second and third highest IgM anticardiolipin titres.
It has often been speculated (but rarely substantiated, except in the case of anti-I21) that the extrapulmonary features of M. pneumoniae infection may have an autoimmune basis. In one of the few studies to address this question directly24 a patient with mycoplasma infection and transverse myelitis was found, by indirect immunofluorescence, to have antibodies directed against central nervous system neurones. The patient improved with plasma exchange. Intriguingly, this patient also had a circulating inhibitor of in vitro coagulation, with features similar to the lupus anticoagulant. As indicated above, this property is very closely linked to the possession ofantiphospholipid antibodies. There are also suggestions that antiphospholipid antibodies from patients with SLE may bind neuronal membrane lipids.25 It is unfortunate that, because of the retrospective nature of our study, we were not able to assess our patients for lupus anticoagulant activity. In patients with SLE this seems to be a more specific predictor of vascular and other complications. 26 A recent retrospective study has identified infection as an important independent risk factor in patients with ischaemic stroke aged under 50 (relative risk 14.5 in the month following infection). 27 The explanation for this is not clear and although changes in haematological variables (such as fibrinogen concentration and platelet count) occurring as acute phase responses could be implicated, the role of antiphospholipid antibodies would seem to be worthy of further investigation (no cases or controls in this study, from Helsinki,27 had mycoplasma infection, suggesting the incidence was low at the time of study). It would be interesting to know whether other infections (such as the principally bacterial infection recorded in the Finnish27 study) are capable of producing antiphospholipid responses of a degree comparable with those seen in mycoplasma infection - Qualitatively, antiphospholipid antibodies are undoubtedly heterogeneous in terms of antigen binding. An infection strongly associated with antiphospholipid antibodies is syphilis. However, the phospholipid binding found here has a different antigenic specificity22 (for neutral and positively charged lipids) from that found in SLE, and is poorly detected by solid phase anticardiolipin assays such as the ELISA described here (reference 23 and unpublished results from our laboratory on 4 high titre VDRL sera, kindly supplied by Mr D. Ellis of the Central Serology Laboratory, Withington Hospital). It therefore seems likely that the antiphospholipid antibodies in mycoplasma infection have a specificity for negatively charged lipids but insufficient data are presented here to draw further comparisons with SLE.
Finally it should be noted that there are some important clinical differences between the extrapulmonary features of mycoplasma infection and the lupus related antiphospholipid antibody syndrome. Neurological disease is relatively common and thrombotic events relatively rare in mycoplasma infection'8 whereas the reverse is true in SLE and in the phospholipid antibody syndrome.'
The thrombocytopenia and fetal loss noted in SLE have not been reported in mycoplasma disease.
It would thus seem unreasonable to draw too close a parallel between these two groups of disorders, and their relation to antiphospholipid antibodies. However, it would be precipitate to consider antiphospholipid antibody responses in M. pneumoniae infection (and possibly other infections) as an entirely irrelevant epiphenomenon.
